Wedbush Has Bearish Estimate for LRMR FY2027 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at Wedbush decreased their FY2027 earnings per share (EPS) estimates for Larimar Therapeutics in a research report issued to clients and investors on Monday, June 23rd. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($1.54) for the year, down from their previous forecast of ($1.12). Wedbush currently has a “Outperform” rating and a $15.00 target price on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics’ FY2028 earnings at $0.18 EPS and FY2029 earnings at $3.80 EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Several other equities analysts have also recently commented on LRMR. HC Wainwright increased their price target on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, March 25th. Guggenheim restated a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday. Robert W. Baird decreased their target price on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Finally, Citigroup reiterated a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $18.50.

Larimar Therapeutics Price Performance

Shares of LRMR stock opened at $3.08 on Thursday. The firm has a fifty day moving average of $2.39 and a two-hundred day moving average of $2.94. The firm has a market cap of $197.21 million, a P/E ratio of -2.07 and a beta of 0.79. Larimar Therapeutics has a 1-year low of $1.61 and a 1-year high of $11.20.

Institutional Investors Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Monimus Capital Management LP acquired a new position in Larimar Therapeutics in the fourth quarter valued at approximately $182,000. Fi3 FINANCIAL ADVISORS LLC lifted its holdings in shares of Larimar Therapeutics by 16.7% in the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company’s stock worth $92,000 after purchasing an additional 3,411 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Larimar Therapeutics by 32.8% in the 4th quarter. American Century Companies Inc. now owns 56,294 shares of the company’s stock worth $218,000 after purchasing an additional 13,891 shares during the last quarter. AXQ Capital LP acquired a new position in Larimar Therapeutics during the 4th quarter valued at approximately $91,000. Finally, EntryPoint Capital LLC boosted its position in Larimar Therapeutics by 197.7% during the 4th quarter. EntryPoint Capital LLC now owns 54,281 shares of the company’s stock valued at $210,000 after purchasing an additional 36,045 shares during the period. Institutional investors and hedge funds own 91.92% of the company’s stock.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.